GLP-1 & MetabolicFDA ApprovedS

Tirzepatide

Mounjaro / Zepbound

Tirzepatide (Mounjaro for T2D, Zepbound for obesity) is Eli Lilly's FDA-approved dual GLP-1/GIP receptor agonist and the first approved twincretin therapy. SURMOUNT-1 trial demonstrated up to 22.5% average body weight reduction at 72 weeks with 15mg — the highest efficacy among approved obesity medications at time of approval. Also approved for obstructive sleep apnea reduction (2024).

XRedditFacebook
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
Studies cited
4
Research grade
S
Community score
125

Trend index

Trackers
2,407

Overview

About Tirzepatide

Tirzepatide (Mounjaro for T2D, Zepbound for obesity) is Eli Lilly's FDA-approved dual GLP-1/GIP receptor agonist and the first approved twincretin therapy. SURMOUNT-1 trial demonstrated up to 22.5% average body weight reduction at 72 weeks with 15mg — the highest efficacy among approved obesity medications at time of approval. Also approved for obstructive sleep apnea reduction (2024).

Category
GLP-1 & Metabolic
Regulatory status
FDA Approved
Also known as
Mounjaro / Zepbound
Self-reports
6

Community

What 6 users report

6 community reports

Positive 0% · Neutral 0% · Negative 100%

Most reported benefits

Appetite
6

Most reported side effects

Nausea
3
Injection site irritation
3

Dose distribution

Median: 2000+ mcg · Most common: 2000+ mcg

0–25
0
25–50
0
50–100
0
100–200
0
200–400
0
400–600
1
600–1000
0
1000–2000
0
2000+
5

Research

Cited research (2)

Help

Frequently asked

What do PeptIQ users report about Tirzepatide?

This page summarizes 6 anonymized self-reports from PeptIQ users who track Tirzepatide, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.

What research is cited for Tirzepatide?

2 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.

Is Tirzepatide safe to use?

This wiki does not assess safety or recommend use. Tirzepatide is listed as FDA Approved. Consult a licensed clinician for personal medical decisions.

What are the purported benefits and uses of Tirzepatide?

Research, primarily in animal models, suggests Tirzepatide may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.

Source

What is the legal status of Tirzepatide?

Tirzepatide is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Tirzepatide as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.

Source

What are the known or theoretical side effects and risks of Tirzepatide?

The safety and effectiveness of Tirzepatide have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.

Source

What is the current state of research on Tirzepatide?

While there are over 200 published studies on Tirzepatide, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.

Source